190 related articles for article (PubMed ID: 20034732)
1. Fanconi anemia pathway heterogeneity revealed by cisplatin and oxaliplatin treatments.
Kachnic LA; Li L; Fournier L; Willers H
Cancer Lett; 2010 Jun; 292(1):73-9. PubMed ID: 20034732
[TBL] [Abstract][Full Text] [Related]
2. FANCD2 but not FANCA promotes cellular resistance to type II topoisomerase poisons.
Kachnic LA; Li L; Fournier L; Ferraiolo N; Dahm-Daphi J; Borgmann K; Willers H
Cancer Lett; 2011 Jun; 305(1):86-93. PubMed ID: 21414716
[TBL] [Abstract][Full Text] [Related]
3. Chemosensitizing tumor cells by targeting the Fanconi anemia pathway with an adenovirus overexpressing dominant-negative FANCA.
Ferrer M; de Winter JP; Mastenbroek DC; Curiel DT; Gerritsen WR; Giaccone G; Kruyt FA
Cancer Gene Ther; 2004 Aug; 11(8):539-46. PubMed ID: 15192709
[TBL] [Abstract][Full Text] [Related]
4. Variation in cisplatinum sensitivity is not associated with Fanconi Anemia/BRCA pathway inactivation in head and neck squamous cell carcinoma cell lines.
Snyder ER; Ricker JL; Chen Z; Waes CV
Cancer Lett; 2007 Jan; 245(1-2):75-80. PubMed ID: 16466850
[TBL] [Abstract][Full Text] [Related]
5. Direct interaction of the Fanconi anaemia protein FANCG with BRCA2/FANCD1.
Hussain S; Witt E; Huber PA; Medhurst AL; Ashworth A; Mathew CG
Hum Mol Genet; 2003 Oct; 12(19):2503-10. PubMed ID: 12915460
[TBL] [Abstract][Full Text] [Related]
6. Disruption of the FA/BRCA pathway in bladder cancer.
Neveling K; Kalb R; Florl AR; Herterich S; Friedl R; Hoehn H; Hader C; Hartmann FH; Nanda I; Steinlein C; Schmid M; Tonnies H; Hurst CD; Knowles MA; Hanenberg H; Schulz WA; Schindler D
Cytogenet Genome Res; 2007; 118(2-4):166-76. PubMed ID: 18000367
[TBL] [Abstract][Full Text] [Related]
7. The BRCA1-interacting helicase BRIP1 is deficient in Fanconi anemia.
Levran O; Attwooll C; Henry RT; Milton KL; Neveling K; Rio P; Batish SD; Kalb R; Velleuer E; Barral S; Ott J; Petrini J; Schindler D; Hanenberg H; Auerbach AD
Nat Genet; 2005 Sep; 37(9):931-3. PubMed ID: 16116424
[TBL] [Abstract][Full Text] [Related]
8. Generation and molecular characterization of head and neck squamous cell lines of fanconi anemia patients.
van Zeeburg HJ; Snijders PJ; Pals G; Hermsen MA; Rooimans MA; Bagby G; Soulier J; Gluckman E; Wennerberg J; Leemans CR; Joenje H; Brakenhoff RH
Cancer Res; 2005 Feb; 65(4):1271-6. PubMed ID: 15735012
[TBL] [Abstract][Full Text] [Related]
9. Downregulation of Fanconi anemia genes in sporadic head and neck squamous cell carcinoma.
Wreesmann VB; Estilo C; Eisele DW; Singh B; Wang SJ
ORL J Otorhinolaryngol Relat Spec; 2007; 69(4):218-25. PubMed ID: 17409780
[TBL] [Abstract][Full Text] [Related]
10. Cellular characterization of cells from the Fanconi anemia complementation group, FA-D1/BRCA2.
Godthelp BC; van Buul PP; Jaspers NG; Elghalbzouri-Maghrani E; van Duijn-Goedhart A; Arwert F; Joenje H; Zdzienicka MZ
Mutat Res; 2006 Oct; 601(1-2):191-201. PubMed ID: 16920162
[TBL] [Abstract][Full Text] [Related]
11. FANCG promotes formation of a newly identified protein complex containing BRCA2, FANCD2 and XRCC3.
Wilson JB; Yamamoto K; Marriott AS; Hussain S; Sung P; Hoatlin ME; Mathew CG; Takata M; Thompson LH; Kupfer GM; Jones NJ
Oncogene; 2008 Jun; 27(26):3641-52. PubMed ID: 18212739
[TBL] [Abstract][Full Text] [Related]
12. Identification of multiple nuclear export sequences in Fanconi anemia group A protein that contribute to CRM1-dependent nuclear export.
Ferrer M; Rodríguez JA; Spierings EA; de Winter JP; Giaccone G; Kruyt FA
Hum Mol Genet; 2005 May; 14(10):1271-81. PubMed ID: 15790592
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of Fanconi Anemia genes in familial breast cancer predisposition.
Seal S; Barfoot R; Jayatilake H; Smith P; Renwick A; Bascombe L; McGuffog L; Evans DG; Eccles D; Easton DF; Stratton MR; Rahman N;
Cancer Res; 2003 Dec; 63(24):8596-9. PubMed ID: 14695169
[TBL] [Abstract][Full Text] [Related]
14. FANCE: the link between Fanconi anaemia complex assembly and activity.
Pace P; Johnson M; Tan WM; Mosedale G; Sng C; Hoatlin M; de Winter J; Joenje H; Gergely F; Patel KJ
EMBO J; 2002 Jul; 21(13):3414-23. PubMed ID: 12093742
[TBL] [Abstract][Full Text] [Related]
15. Genetic subtyping of Fanconi anemia by comprehensive mutation screening.
Ameziane N; Errami A; Léveillé F; Fontaine C; de Vries Y; van Spaendonk RM; de Winter JP; Pals G; Joenje H
Hum Mutat; 2008 Jan; 29(1):159-66. PubMed ID: 17924555
[TBL] [Abstract][Full Text] [Related]
16. Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors.
Taniguchi T; Tischkowitz M; Ameziane N; Hodgson SV; Mathew CG; Joenje H; Mok SC; D'Andrea AD
Nat Med; 2003 May; 9(5):568-74. PubMed ID: 12692539
[TBL] [Abstract][Full Text] [Related]
17. Assessing the spectrum of germline variation in Fanconi anemia genes among patients with head and neck carcinoma before age 50.
Chandrasekharappa SC; Chinn SB; Donovan FX; Chowdhury NI; Kamat A; Adeyemo AA; Thomas JW; Vemulapalli M; Hussey CS; Reid HH; Mullikin JC; Wei Q; Sturgis EM
Cancer; 2017 Oct; 123(20):3943-3954. PubMed ID: 28678401
[TBL] [Abstract][Full Text] [Related]
18. Targeted disruption of FANCC and FANCG in human cancer provides a preclinical model for specific therapeutic options.
Gallmeier E; Calhoun ES; Rago C; Brody JR; Cunningham SC; Hucl T; Gorospe M; Kohli M; Lengauer C; Kern SE
Gastroenterology; 2006 Jun; 130(7):2145-54. PubMed ID: 16762635
[TBL] [Abstract][Full Text] [Related]
19. Compromised Fanconi anemia response due to BRCA1 deficiency in cisplatin-sensitive head and neck cancer cell lines.
Burkitt K; Ljungman M
Cancer Lett; 2007 Aug; 253(1):131-7. PubMed ID: 17321670
[TBL] [Abstract][Full Text] [Related]
20. Map of synthetic rescue interactions for the Fanconi anemia DNA repair pathway identifies USP48.
Velimezi G; Robinson-Garcia L; Muñoz-Martínez F; Wiegant WW; Ferreira da Silva J; Owusu M; Moder M; Wiedner M; Rosenthal SB; Fisch KM; Moffat J; Menche J; van Attikum H; Jackson SP; Loizou JI
Nat Commun; 2018 Jun; 9(1):2280. PubMed ID: 29891926
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
